tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
PremiumRatingsAbivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
22d ago
Abivax announces trading resumption of shares on Euronext Paris
Premium
The Fly
Abivax announces trading resumption of shares on Euronext Paris
22d ago
Abivax $400M Spot Secondary; price range $62.50-$65.00
Premium
The Fly
Abivax $400M Spot Secondary; price range $62.50-$65.00
23d ago
Abivax upgraded to Overweight at Morgan Stanley after obefazimod data
PremiumThe FlyAbivax upgraded to Overweight at Morgan Stanley after obefazimod data
23d ago
Abivax price target raised to $101 from $50 at Guggenheim
Premium
The Fly
Abivax price target raised to $101 from $50 at Guggenheim
23d ago
Abivax price target raised to $70 from $42 at Piper Sandler
Premium
The Fly
Abivax price target raised to $70 from $42 at Piper Sandler
23d ago
Abivax SA – American Depositary Shares trading halted, news pending
PremiumThe FlyAbivax SA – American Depositary Shares trading halted, news pending
24d ago
Citizens JMP healthcare analysts hold an analyst/industry conference call
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
1M ago
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
Premium
Ratings
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100